Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression

• Hyo Jin Kim,
• Thomas Witzig,
• Stephen M Ansell,
• N Nora Bennani,
• Levi D Pederson,
• Pamela J Atherton,
• Ivana N Micallef,
• Gita Thanarajasingam,
• Grzegorz S Nowakowski,
• Andrew L Feldman

Affiliations

Hyo Jin Kim

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

Thomas Witzig

Aff1 grid.66875.3a000000040459167XMayo Clinic Rochester MN USA

Stephen M Ansell

Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA

N Nora Bennani

Division of Hematology, Mayo Clinic, Rochester, MN, USA

Levi D Pederson

Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

Pamela J Atherton

Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA

Ivana N Micallef

Division of Hematology, Mayo Clinic, Rochester, MN, USA

Gita Thanarajasingam

Division of Hematology, Mayo Clinic, Rochester, MN, USA

Grzegorz S Nowakowski

Division of Hematology, Mayo Clinic, Rochester, MN, USA

Andrew L Feldman

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA